Citigroup Maintains Neutral on Establishment Labs Hldgs, Raises Price Target to $47
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time intelligence to help them succeed in the stock market.
Community and Exclusivity: Joining Benzinga Pro connects users with over 10,000 serious traders and grants access to exclusive stories and insights from Benzinga reporters.
Trade with 70% Backtested Accuracy
Analyst Views on ESTA
About ESTA
About the author
Vanguard Health Care ETF Sees 14.9% Insider Buying in Holdings
- Insider Buying Ratio: The Vanguard Health Care ETF (VHT) shows that 14.9% of its holdings have experienced insider buying in the past six months, indicating strong confidence from executives that could positively influence investor sentiment.
- Teleflex Activity: Teleflex (TFX), comprising 0.07% of VHT, has seen 5 directors and officers purchase shares in the last six months, suggesting internal optimism about its stock price, which may bolster market confidence in the company.
- Establishment Labs Activity: Establishment Labs (ESTA), ranked 216th in VHT with a holding value of approximately $3,464,977, recently had 2 directors and officers file Form 4s indicating purchases, reflecting a positive outlook on the company's future growth.
- ETF Holding Value: The Vanguard Health Care ETF holds a total of $13,702,466 worth of TFX, making it the 106th largest holding, showcasing the ETF's strategic investment in the healthcare sector, which may attract more investors focused on this industry.
Establishment Labs CEO to Present at J.P. Morgan Healthcare Conference on January 14, 2026
- Executive Presentation: Establishment Labs CEO Peter Caldini and CFO Raj Denhoy will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 9:45 AM PT, showcasing the company's latest advancements in women's health.
- Live Webcast: The presentation will be available via a live webcast on Establishment Labs' investor relations website, allowing global investors to gain real-time insights into the company's strategic direction and market dynamics, thereby enhancing investor confidence.
- Product Innovation: Establishment Labs has delivered over four million Motiva® devices since 2010, establishing the company as a leader in breast aesthetics and reconstruction, significantly improving patient satisfaction and safety standards.
- Technological Strength: With over 200 patent applications and more than 100 scientific studies, the company demonstrates its innovative capabilities and competitive edge in the women's health technology sector.
Establishment Labs CEO to Present at 2026 J.P. Morgan Healthcare Conference
- Executive Presentation Schedule: Establishment Labs CEO Peter Caldini and CFO Raj Denhoy will present at the J.P. Morgan Healthcare Conference on January 14, 2026, showcasing the company's latest advancements in women's health, which is expected to attract investor interest.
- Technology Innovation Showcase: The company is dedicated to improving women's health through science and engineering, offering breast aesthetics and reconstruction solutions in over 90 countries, demonstrating its extensive influence in the global market.
- Product Delivery Achievement: Since 2010, Establishment Labs has delivered over 4 million Motiva® devices, establishing a new standard for safety and patient satisfaction, further solidifying its leadership position in the medical device industry.
- R&D Strength: With over 200 patent applications and more than 100 scientific studies, the company demonstrates its ongoing innovation capabilities in breast health, which is expected to drive future market growth.
Establishment Labs Submits Motiva Implants for FDA Approval in Breast Reconstruction
- FDA Approval Expansion: Establishment Labs has submitted Motiva implants for breast reconstruction approval, marking a significant advancement in women's health and expected to meet the urgent market demand for innovative reconstruction technologies.
- Clinical Study Results: The Motiva U.S. IDE study, conducted at 17 U.S. centers and one European center, included 274 patients, demonstrating the product's effectiveness in breast reconstruction, which could enhance the company's market share in the medical technology sector.
- Technological Innovation: Motiva implants feature a SmoothSilk® surface designed for enhanced biocompatibility and reduced inflammation, which is expected to improve patient satisfaction and surgical outcomes, further solidifying the company's leadership position in the industry.
- Market Potential: Since receiving approval for breast augmentation in 2024, over 60,000 Motiva implants have been sold in the U.S., indicating strong market demand, and the recent approval for reconstruction indications is anticipated to further drive sales growth.
17.0% of FHLC Holdings Experiencing Recent Insider Purchases
Insider Buying Activity: 17.0% of the weighted holdings in the Fidelity MSCI Health Care Index ETF (FHLC) have seen insider buying in the past six months.
Avantor Inc (AVTR): This company, making up 0.12% of FHLC, has had two directors and officers purchase shares recently, with the ETF holding $3,215,377 worth of AVTR.
Establishment Labs Holdings Inc (ESTA): Representing approximately 0.02% of FHLC, ESTA has also seen insider purchases from two directors and officers, with the ETF holding $490,723 worth of ESTA.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Establishment Labs Holdings (ESTA) Rises Over 27% Following Q3 2025 Earnings Report
Company Performance: Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported Q3 2025 revenue of $53.78 million, a 33.7% year-over-year increase, exceeding analyst estimates by $1.5 million, while the EPS of negative $0.38 also surpassed expectations.
Growth in US Market: The company's US business, a key growth area, saw a 16% increase despite a seasonally slower quarter for breast procedures, with management anticipating a 20% market share in US breast augmentation by the end of 2025.
Sales Acceleration: Management noted that the fourth quarter is typically the strongest for breast augmentation, and they are already observing sales acceleration in the US market.
Investment Considerations: While ESTA shows potential as an investment, the article suggests that certain AI stocks may offer better upside potential and lower downside risk.
Vanguard Health Care ETF Sees 14.9% Insider Buying in Holdings
- Insider Buying Ratio: The Vanguard Health Care ETF (VHT) shows that 14.9% of its holdings have experienced insider buying in the past six months, indicating strong confidence from executives that could positively influence investor sentiment.
- Teleflex Activity: Teleflex (TFX), comprising 0.07% of VHT, has seen 5 directors and officers purchase shares in the last six months, suggesting internal optimism about its stock price, which may bolster market confidence in the company.
- Establishment Labs Activity: Establishment Labs (ESTA), ranked 216th in VHT with a holding value of approximately $3,464,977, recently had 2 directors and officers file Form 4s indicating purchases, reflecting a positive outlook on the company's future growth.
- ETF Holding Value: The Vanguard Health Care ETF holds a total of $13,702,466 worth of TFX, making it the 106th largest holding, showcasing the ETF's strategic investment in the healthcare sector, which may attract more investors focused on this industry.
Establishment Labs CEO to Present at J.P. Morgan Healthcare Conference on January 14, 2026
- Executive Presentation: Establishment Labs CEO Peter Caldini and CFO Raj Denhoy will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 9:45 AM PT, showcasing the company's latest advancements in women's health.
- Live Webcast: The presentation will be available via a live webcast on Establishment Labs' investor relations website, allowing global investors to gain real-time insights into the company's strategic direction and market dynamics, thereby enhancing investor confidence.
- Product Innovation: Establishment Labs has delivered over four million Motiva® devices since 2010, establishing the company as a leader in breast aesthetics and reconstruction, significantly improving patient satisfaction and safety standards.
- Technological Strength: With over 200 patent applications and more than 100 scientific studies, the company demonstrates its innovative capabilities and competitive edge in the women's health technology sector.
Establishment Labs CEO to Present at 2026 J.P. Morgan Healthcare Conference
- Executive Presentation Schedule: Establishment Labs CEO Peter Caldini and CFO Raj Denhoy will present at the J.P. Morgan Healthcare Conference on January 14, 2026, showcasing the company's latest advancements in women's health, which is expected to attract investor interest.
- Technology Innovation Showcase: The company is dedicated to improving women's health through science and engineering, offering breast aesthetics and reconstruction solutions in over 90 countries, demonstrating its extensive influence in the global market.
- Product Delivery Achievement: Since 2010, Establishment Labs has delivered over 4 million Motiva® devices, establishing a new standard for safety and patient satisfaction, further solidifying its leadership position in the medical device industry.
- R&D Strength: With over 200 patent applications and more than 100 scientific studies, the company demonstrates its ongoing innovation capabilities in breast health, which is expected to drive future market growth.
Establishment Labs Submits Motiva Implants for FDA Approval in Breast Reconstruction
- FDA Approval Expansion: Establishment Labs has submitted Motiva implants for breast reconstruction approval, marking a significant advancement in women's health and expected to meet the urgent market demand for innovative reconstruction technologies.
- Clinical Study Results: The Motiva U.S. IDE study, conducted at 17 U.S. centers and one European center, included 274 patients, demonstrating the product's effectiveness in breast reconstruction, which could enhance the company's market share in the medical technology sector.
- Technological Innovation: Motiva implants feature a SmoothSilk® surface designed for enhanced biocompatibility and reduced inflammation, which is expected to improve patient satisfaction and surgical outcomes, further solidifying the company's leadership position in the industry.
- Market Potential: Since receiving approval for breast augmentation in 2024, over 60,000 Motiva implants have been sold in the U.S., indicating strong market demand, and the recent approval for reconstruction indications is anticipated to further drive sales growth.
17.0% of FHLC Holdings Experiencing Recent Insider Purchases
Insider Buying Activity: 17.0% of the weighted holdings in the Fidelity MSCI Health Care Index ETF (FHLC) have seen insider buying in the past six months.
Avantor Inc (AVTR): This company, making up 0.12% of FHLC, has had two directors and officers purchase shares recently, with the ETF holding $3,215,377 worth of AVTR.
Establishment Labs Holdings Inc (ESTA): Representing approximately 0.02% of FHLC, ESTA has also seen insider purchases from two directors and officers, with the ETF holding $490,723 worth of ESTA.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Establishment Labs Holdings (ESTA) Rises Over 27% Following Q3 2025 Earnings Report
Company Performance: Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported Q3 2025 revenue of $53.78 million, a 33.7% year-over-year increase, exceeding analyst estimates by $1.5 million, while the EPS of negative $0.38 also surpassed expectations.
Growth in US Market: The company's US business, a key growth area, saw a 16% increase despite a seasonally slower quarter for breast procedures, with management anticipating a 20% market share in US breast augmentation by the end of 2025.
Sales Acceleration: Management noted that the fourth quarter is typically the strongest for breast augmentation, and they are already observing sales acceleration in the US market.
Investment Considerations: While ESTA shows potential as an investment, the article suggests that certain AI stocks may offer better upside potential and lower downside risk.
